Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel amyloid beta oligomer specific binding molecule

An amyloid and binding molecule technology, applied in the direction of immunoglobulin, anti-animal/human immunoglobulin, specific peptide, etc., can solve the problems of product instability and aggregation, poor tissue penetration, etc.

Active Publication Date: 2019-10-11
DEGENRX BV
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite their success, therapeutic monoclonal antibodies have certain limitations such as: limited activity against certain types of antigens, poor tissue penetration, unwanted effector functions in many cases, cost of manufacture, Product instability and aggregation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel amyloid beta oligomer specific binding molecule
  • Novel amyloid beta oligomer specific binding molecule
  • Novel amyloid beta oligomer specific binding molecule

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0066] IgNARs / vNARs - Overview

[0067] Cartilaginous fishes (sharks, rays, rays and chimaeras) express three distinct antibody isotypes: IgM, IgNAR (immunoglobulin neoantigen receptor) and primitive IgW (primordial IgW) (Rumfelt LL. et al. BMC immunology 2004 ; 5:8; Rumfelt LL et al. Journal of Immunology 2004; 173:1 129-39). IgNAR was first identified in the serum of the nurse shark (Ginglymostoma cirratum) (Greenberg AS et al. Nature 1995;374:168-73). IgNARs are heavy chain homodimers lacking light chains. Each chain in the secreted form consists of one variable region followed by five constant regions, the latter four being homologous to IgW constant regions. The antigen binding site is formed by only a single domain, called "vNAR" (variable region of neoantigen receptor). Serum IgNAR levels range from about 0.1 mg / ml to 1 mg / ml.

[0068] To date, all IgNARs identified have been reported to have a minimal variable loop region similar to the conventional CDR1 and CDR2 l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure relates to an amyloid beta peptide (A beta)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.

Description

technical field [0001] The present invention is in the field of neurodegenerative diseases, in particular to conditions with a beta-amyloid component, including in humans and non-human animals: Alzheimer's disease (AD), vascular dementia (VD), dementia, pre-dementia , Cognitive Dysfunction Syndrome (CDS) and Cognitive Loss. Background technique [0002] Alzheimer's disease (AD) is clinically characterized by a progressive and gradual decline in cognitive function. Neuropathology AD is characterized by the hallmark findings of neurofibrillary tangles and senile plaques, in addition to the presence of nerve fiber threads, specific neuronal loss, and synapse loss. Measures of pathology relate to the density of neuroinflammatory amyloid plaques in affected brain regions. For the diagnosis of AD, the presence in the brain parenchyma of (mostly) neuritic plaques composed of highly insoluble amyloid beta (Aβ) peptides is required. [0003] Amyloid β (Aβ) means a peptide of gener...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18
CPCC07K16/18C07K2317/20C07K2317/567C07K2317/569C07K2317/92A61P25/00A61P25/14A61P25/16A61P25/28A61P43/00C12N15/86G01N2333/4709G01N33/6896
Inventor 萨曼莎·凯瑟琳·科布迈克尔·福利奥古斯蒂努斯·彼得鲁斯·亨里克斯·谢夫哈尔斯阿曼德·维尔布兰特·雅内斯·维歇特·泰珀
Owner DEGENRX BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com